# Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients

> **NCT01257451** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 431 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Vildagliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01257451
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 431 (ACTUAL)
- **Last updated:** 2012-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01257451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01257451, "Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01257451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*